Prevention of Vascular Access Graft Failure in Patients With Chronic Renal Failure Requiring Hemodialysis
A Phase 1/2, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Pilot Trial to Assess the Effect of Treatment of the Recipient Vein of a Polytetrafluoroethylene (PTFE) Vascular Access Graft With Two Concentrations of E2F Decoy as Compared to Placebo on Neointimal Hyperplasia and the Preservation of Graft Function in Patients With Chronic Renal Failure Requiring Hemodialysis
Sponsor: Anesiva, Inc.
A PHASE1/PHASE2 clinical study on Chronic Renal Failure and Hyperplasia, this trial is terminated or withdrawn. The trial is conducted by Anesiva, Inc. and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE1_PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE1_PHASE2
First recorded
May 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Anesiva, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Atlanta, United States, Baton Rouge, United States, Charlottesville, United States, Chicago, United States, Detroit, United States, Greenville, United States, Hudson, United States, Indianapolis, United States, Lansing, United States, Los Angeles, United States and 8 more location s